Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Response rate Data collection of the efficacity of PD-1 inhibitors
研究概览
简要总结
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
详细描述
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic uveal melanoma
- •Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment
排除标准
- •Antecedent of another evolutionary tumor pathology
结局指标
主要结局
Response rate Data collection of the efficacity of PD-1 inhibitors
时间窗: December 2019
Description of Response rate
Objective response Data collection of the efficacity of PD-1 inhibitors
时间窗: December 2019
Description of Objective response
Progression Free Survival Data collection of the efficacity of PD-1 inhibitors
时间窗: December 2019
Description of PFS (Progression Free Survival)
Global Survival Data collection of the efficacity of PD-1 inhibitors
时间窗: December 2019
Description of Global Survival
Stability Data collection of the efficacity of PD-1 inhibitors
时间窗: December 2019
Description of Stability at 6 months
次要结局
- Exploration of PD-1 inhibitors biomarkers(December 2019)